BRAF and melanoma: The nexturastat A-mediated inhibition of the conversion of anticancer M1-polarized macrophages to pro-tumorigenic M2-polarized was applied for further immune therapeutic strategies to treat BRAF-mutant melanomas, such as adoptive cell therapy with reprogrammed/nexturastat A-treated M1-polarized macrophages and anti-CD47 therapy[121,122].